| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 94.78 +6.29% on 04/08/25 |
Period Open: 113.56
| 114.68 -12.16% on 03/17/25 | -12.82 (-11.29%) since 03/14/25 |
| 3-Month | 94.78 +6.29% on 04/08/25 |
Period Open: 125.99
| 137.25 -26.60% on 02/10/25 | -25.25 (-20.04%) since 01/16/25 |
| 52-Week | 91.57 +10.02% on 08/08/24 |
Period Open: 97.83
| 137.25 -26.60% on 02/10/25 | +2.91 (+2.97%) since 04/16/24 |
ANA InterContinental Tokyo unveils Icon Reborn transformation
InterContinental Hotels Group PLC (the Company)
LONDON, UK / ACCESSWIRE / December 27, 2024 / The Company announces that on 24 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International...
Purchase of own shares
InterContinental Hotels Group PLC (the Company)
LONDON, UNITED KINGDOM / ACCESSWIRE / December 20, 2024 / The Company announces that on 19 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman...
LONDON, UNITED KINGDOM / ACCESSWIRE / December 19, 2024 / The Company announces that on 18 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman...
LONDON, UNITED KINGDOM / ACCESSWIRE / December 18, 2024 / The Company announces that on 17 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman...
Purchase of own shares
Purchase of own shares
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Patient Enrollment on Track Topline Results Currently Expected Mid-Calendar Year 2023...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15,...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14,...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Patient Enrollment on Track Topline Results Currently Expected Mid-Calendar Year 2023...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15,...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Size of 350 patients Topline Results...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2023 operating results on Monday, November 14,...
/PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...
| Symbol | %Holdings | 3M %Chg |
|---|---|---|
| IHG | -20.04% | |
| Intercontinental Hotels Group ADR | ||
| VEA | 0.09% | +3.89% |
| FTSE Developed Markets Vanguard | ||
| VXUS | 0.06% | +2.52% |
| Total Intl Stock ETF Vanguard | ||
| CGGO | 0.85% | -8.61% |
| Capital Global Growth Equity ETF | ||
| SCHF | 0.09% | +4.33% |
| Schwab Intl Equity ETF | ||
| VGK | 0.17% | +6.92% |
| Europe ETF FTSE Vanguard | ||
| Symbol | %Holdings | 3M %Chg |
|---|---|---|
| IHG | -20.04% | |
| Intercontinental Hotels Group ADR | ||
| CRUZ | 3.95% | -18.50% |
| DeFiance Hotel Airline and Cruise ETF | ||
| IDVO | 0.82% | -0.20% |
| Amplify Intl Enhanced Dividend Income ETF | ||
| CGUS | 0.65% | -10.64% |
| Capital Core Equity ETF | ||
| GINN | 0.18% | -11.50% |
| Goldman Sachs Innovate Equity ETF | ||
| VGK | 0.17% | +6.92% |
| Europe ETF FTSE Vanguard | ||
| 3rd Resistance Point | 104.47 |
| 2nd Resistance Point | 103.51 |
| 1st Resistance Point | 102.13 |
| Last Price | 100.74 |
| 1st Support Level | 99.78 |
| 2nd Support Level | 98.82 |
| 3rd Support Level | 97.44 |
| 52-Week High | 137.25 |
| Fibonacci 61.8% | 119.80 |
| Fibonacci 50% | 114.41 |
| Fibonacci 38.2% | 109.02 |
| Last Price | 100.74 |
| 52-Week Low | 91.57 |
